ONABOTULINUMTOXINA IS WELL TOLERATED IN CHRONIC MIGRAINE PATIENTS TAKING ORAL PREVENTIVE MEDICATIONS: LONG-TERM COMPEL ANALYSIS BY TREATMENT CYCLE

被引：0
|
作者：
Winner, Paul K. [1 ]
Blumenfeld, Andrew M. [2 ]
Eross, Eric J. [3 ]
Orejudos, Amelia [4 ]
Adams, Aubrey Manack [4 ]
Brin, Mitchell F. [4 ,5 ]
机构：
[1] Palm Beach Headache Ctr, Premiere Res Inst Palm Beach Neurol, W Palm Beach, FL USA
[2] Headache Ctr Southern Calif, Neurol Ctr, Carlsbad, CA 92011 USA
[3] Phoenix Headache Inst, Scottsdale, AZ USA
[4] Allergan Plc, Irvine, CA USA
[5] Univ Calif Irvine, Irvine, CA USA
来源：
TOXICON | 2018年 / 156卷
关键词：
Adverse events; Chronic migraine; COMPEL; Concomitant medication; OnabotulinumtoxinA; Safety;
D O I：
10.1016/j.toxicon.2018.11.274
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
264
引用
收藏
页码：S114 / S114
页数：1
相关论文
共 50 条
  • [41] Descriptive comparison of the efficacy and safety of onabotulinumtoxina for headache prophylaxis in adult chronic migraine patients from two long-term, multicenter studies: compel vs. Preempt
    Aurora, S.
    Stark, R.
    Reppine, A.
    Adams, A. Manack
    Blumenfeld, A.
    CEPHALALGIA, 2015, 35 : 47 - 47
  • [42] Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL
    Blumenfeld, Andrew
    Stark, Richard
    Adams, Aubrey Manack
    Orejudos, Amelia
    Aurora, Sheena
    NEUROLOGY, 2017, 88
  • [43] Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study
    Young, William B.
    Lopez, J. Ivan
    Rothrock, John F.
    Orejudos, Amelia
    Adams, Aubrey Manack
    Lipton, Richard B.
    Blumenfeld, Andrew M.
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (1):
  • [44] Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL
    Blumenfeld, Andrew
    Stark, Richard
    Adams, Aubrey Manack
    Orejudos, Amelia
    Aurora, Sheena
    NEUROLOGY, 2017, 88
  • [45] Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study
    William B. Young
    J. Ivan Lopez
    John F. Rothrock
    Amelia Orejudos
    Aubrey Manack Adams
    Richard B. Lipton
    Andrew M. Blumenfeld
    The Journal of Headache and Pain, 2019, 20
  • [46] OnabotulinumtoxinA in chronic migraine: long-term efficacy in a prophylactic medication free cohort
    di Cola, Francesca Schiano
    Pari, Elisa
    Caratozzolo, Salvatore
    Mancinelli, Chiara
    Liberini, Paolo
    Rao, Renata
    Padovani, Alessandro
    NEUROLOGICAL SCIENCES, 2018, 39 : S159 - S160
  • [47] Long-term effectiveness of eptinezumab in patients with prior preventive migraine treatment failures
    Starling, A.
    Ashina, M.
    Tepper, S.
    Gendolla, A.
    Sperling, B.
    Ettrup, A.
    Josiassen, M.
    HEADACHE, 2023, 63 : 144 - 145
  • [48] Descriptive Comparison of the Efficacy and Safety of OnabotulinumtoxinA for Headache Prophylaxis in Adult Chronic Migraine Patients from Two Long-term, Multicenter Studies: COMPEL vs. PREEMPT
    Aurora, S.
    Stark, R.
    Reppine, A.
    Adams, Manack A.
    Blumenfeld, A.
    HEADACHE, 2015, 55 : 142 - 142
  • [49] Long-term effectiveness of eptinezumab in patients with prior preventive migraine treatment failures
    Ashina, M.
    Tepper, S.
    Gendolla, A.
    Sperling, B.
    Ettrup, A.
    Josiassen, M.
    Starling, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 372 - 372
  • [50] OnabotulinumtoxinA in chronic migraine: long-term efficacy in a prophylactic medication free cohort
    Francesca Schiano di Cola
    Elisa Pari
    Salvatore Caratozzolo
    Chiara Mancinelli
    Paolo Liberini
    Renata Rao
    Alessandro Padovani
    Neurological Sciences, 2018, 39 : 159 - 160
12345